Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
This research is being done in order to improve treatment outcomes in patients diagnosed
with bulky, early stage Hodgkin lymphoma and to reduce the side effects that are associated
with use of radiation used in current treatments. The chemotherapy treatment in this study
consists of a combination of four drugs approved by the Food and Drug Administration (FDA):
doxorubicin, bleomycin, vinblastine, and dacarbazine. This regimen (called ABVD) has been
found to be effective in treating patients with Hodgkin lymphoma and is considered the
standard of treatment used with radiation therapy in patients with bulky early stage Hodgkin
lymphoma. As part of the evaluation of the effectiveness of the chemotherapy treatment, PET
scans will be obtained during the course of therapy. The usefulness of this PET scan will be
evaluated to determine whether radiation may be left out in the treatment of disease if the
PET scan shows that the patient has responded to chemotherapy alone. The plan is to identify
a group of patients using early PET scans in order to change to a chemotherapy treatment
called BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine and prednisone). It is one of the most highly effective chemotherapy regimens
for Hodgkin lymphoma, but is associated with more side effects than ABVD. Although it has
become standard of care in Europe, its use has been more limited in the U.S. because of
concerns about toxicity.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.